AdvanCell (Series D)
Funding Details
Awarder
Inbox
Date Award
July 16, 2026
Vertical
Healthcare
Funding URL
View Funding Page
Funding Amount
$315,000,000
Company Info
Market
Cancer treatment
Location
Cambridge, MA, USA
Coinvestors
Abingworth, Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Brandon Capital Partners, Catalio Capital, Eli Lilly Ventures, Eventide Asset Management, Fidelity Management & Research Company, Morningside Group, Piper Heartland Healthcare Capital, Sanofi Ventures, SV Health Investors, Symbiosis, T. Rowe Price Associates, Tenmile, Velosity Capital
Company Description

AdvanCell is a clinical-stage radiopharmaceutical company developing next-generation targeted alpha therapies for cancer. Through its vertically integrated platform spanning proprietary Lead-212 technology, secure isotope supply, advanced manufacturing and clinical development, the Company is unlocking the full potential of targeted alpha therapy.

Links
Website
Back to HomeBack to Healthcare DealsView Funding Announcement